Document Detail


Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL).
MedLine Citation:
PMID:  22047708     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Although vitamin D insufficiency is related to inferior prognosis in some cancers, limited data exist in hematologic malignancies. We evaluated the relationship between 25(OH)D serum levels and time to first treatment (TFT), a disease-specific end point, in 130 previously untreated Binet stage A chronic lymphocytic leukemia (CLL) patients. Measurement of 25(OH)D was performed by means of a direct, competitive chemiluminescence immunoassay using the DiaSorin LIAISON 25(OH)D TOTAL assay (DiaSorin, Inc., Stillwater, Minnesota). Overall, 41 patients (31.5%) had severe vitamin D insufficiency (<10ng/mL), 66 (50.7%) had mild to moderate insufficiency (10-24ng/mL), and 23 (17.6%) had 25(OH)D levels within the optimal range (25-80ng/mL), with no relationship with between the season of sample collection and 25(OH)D level (P=0.188). A patient stratification according to these 3 groups led to significant difference in terms of TFT, with vitamin D insufficient patients having the shortest TFT (P=0.02). With respect to continuous 25(OH)D levels and clinical outcome, TFT was shorter as 25(OH)D decreased until a value of 13.5ng/mL at which point the association of 25(OH)D and TFT remained constant. As a matter of fact, the 25(OH)D value of 13.5ng/mL identified two patients subsets with different TFT risk (HR=1.91; 95% CI=1.06-3.44; P=0.03). In multivariate analysis the variable entering the model at a significant level were mutational status of IgVH (P<0.0001), serum thymidine kinase (P=0.02) and absolute lymphocyte count (P=0.03). Thus confirming the Mayo clinic experience, our data provide further evidence that 25(OH)D levels may be an important host factor influencing TFT of Binet stage A patients. Whether normalizing vitamin D levels may delay disease-progression of patients with early disease will require testing in future trials.
Authors:
Stefano Molica; Giovanna Digiesi; Anna Antenucci; Luciano Levato; Rosanna Mirabelli; Matteo Molica; Massimo Gentile; Diana Giannarelli; Isabella Sperduti; Fortunato Morabito; Laura Conti
Related Documents :
1672858 - Neurohormonal factors in functional dyspepsia: insights on pathophysiological mechanisms.
881098 - A comparison of a new slow release aspirin ("slow aspirin") with plain aspirin in the t...
8406148 - Disturbed gastric emptying in the short bowel syndrome. evidence for a 'colonic brake'.
15447748 - Relationship between partial gastric volumes and dyspeptic symptoms in fundoplication p...
15471928 - Diagnostic assessment of the developmental potential of human cryopreserved ovarian tis...
20726408 - The incidence of benign and malignant neoplasia presenting as acute appendicitis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-10-31
Journal Detail:
Title:  Leukemia research     Volume:  -     ISSN:  1873-5835     ISO Abbreviation:  -     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-11-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Affiliation:
Dipartimento di Emato-oncologia, Azienda Ospedaliera di Catanzaro, Catanzaro, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes i...
Next Document:  DNA repair gene XPD and XRCC1 polymorphisms and the risk of febrile neutropenia and mucositis in chi...